Initial Therapy of Advanced Anaplastic Thyroid Cancer via Targeting VEGFR-2: A Case Report
Initial Therapy of Advanced Anaplastic Thyroid Cancer via Targeting VEGFR-2: A Case Report
复制标题
通过靶向 VEGFR-2 治疗晚期甲状腺未分化癌：病例报告
DOI：
10.2147/ott.s223727
复制
发表时间：
2019-01-01
影响因子：
4
通讯作者：
Chen, Libo
中科院分区：
文献类型：
--
作者：
Cheng, Lin;Jiao, Qiong;Chen, Libo
摘要 临床前研究表明，阿帕替尼主要靶向血管内皮生长因子受体2（VEGFR-2），可在体外和体内抑制甲状腺未分化癌（ATC）细胞的增殖。然而，ATC 患者的疗效和安全性仍不清楚。在此，我们报告一名 93 岁女性晚期 ATC 患者的病例，她最初接受阿帕替尼治疗。开始治疗4周后，肿瘤明显缩小，并持续了30多周。颈部 CT 显示疾病稳定，原发灶的最佳反应率为 19.7%，且转移淋巴结缩小。观察到不良事件，包括高血压、牙齿溃疡、手足综合征、疲劳和厌食，并通过支持治疗和减少剂量减轻了不良事件。患者的总生存期为 41 周。这是第一份描述 VEGFR-2 抑制剂治疗晚期 ATC 有效性的报告，需要临床试验来进一步确定其在这一具有挑战性的环境中的效用。
Abstract Preclinical studies have demonstrated that Apatinib, major targeting vascular endothelial growth factor receptor-2 (VEGFR-2), could inhibit the proliferation of anaplastic thyroid carcinoma (ATC) cells in vitro and in vivo. The efficacy and safety in ATC patients, however, remains unknown. Here, we report the case of a 93-year-old female with advanced ATC who initially treated with Apatinib. The tumor shrank notably 4 weeks after the initiation of therapy, which sustained for more than 30 weeks. The cervical CT illuminated a stable disease with a best response of 19.7% of the primary lesion and shrinkage of the metastatic lymph node. Adverse events, including hypertension, dental ulcer, hand-foot syndrome, fatigue, and anorexia, were observed and lightened with supportive treatment and dose reductions. The overall survival of the patient was 41 weeks. This is the first report describing the effectiveness of the VEGFR-2 inhibitor for the treatment of advanced ATC, warranting clinical trials to further ascertain its utility in this challenging setting.